BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 26463904)

  • 1. [Nalmefene and Opioid Withdrawal Syndrome: Analysis of the Global Pharmacovigilance Database for Adverse Drug Reactions].
    Dahmke H; Kupferschmidt H; Kullak-Ublick GA; Weiler S
    Praxis (Bern 1994); 2015 Oct; 104(21):1129-34. PubMed ID: 26463904
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Illogical association nalmefene and opioids: Analysis in the French pharmacovigilance database].
    Favrelière S; Lafay-Chebassier C; Fauconneau B; Quillet A; Yéléhé-Okouma M; Montastruc F; Pérault-Pochat MC
    Therapie; 2019 Jun; 74(3):369-374. PubMed ID: 30197228
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Severe opioid withdrawal syndrome after a single dose of nalmefene.
    Donnerstag N; Schneider T; Lüthi A; Taegtmeyer A; Raetz Bravo A; Mehlig A
    Eur J Clin Pharmacol; 2015 Aug; 71(8):1025-6. PubMed ID: 26050241
    [No Abstract]   [Full Text] [Related]  

  • 4. Opioid substitution therapy or hidden opioids are a minefield for nalmefene: an atypical case series of 11 patients in Lorraine.
    Yéléhé-Okouma M; Martini H; Lemarié J; Labroca P; Petitpain N; Gibaja V; Paille F; Gillet P
    Fundam Clin Pharmacol; 2017 Oct; 31(5):574-579. PubMed ID: 28322465
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Assessment of nalmefene glucuronide as a selective gut opioid antagonist.
    Cheskin LJ; Chami TN; Johnson RE; Jaffe JH
    Drug Alcohol Depend; 1995 Aug; 39(2):151-4. PubMed ID: 8529534
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Management of precipitated opiate withdrawal syndrome induced by nalmefene mistakenly prescribed in opiate-dependent patients: a review for clinicians.
    Franchitto N; Jullian B; Salles J; Pelissier F; Rolland B
    Expert Opin Drug Metab Toxicol; 2017 Jun; 13(6):669-677. PubMed ID: 28343423
    [TBL] [Abstract][Full Text] [Related]  

  • 7. ▼Nalmefene for alcohol dependence.
    Drug Ther Bull; 2014 May; 52(5):54-7. PubMed ID: 24809337
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeted nalmefene with simple medical management in the treatment of heavy drinkers: a randomized double-blind placebo-controlled multicenter study.
    Karhuvaara S; Simojoki K; Virta A; Rosberg M; Löyttyniemi E; Nurminen T; Kallio A; Mäkelä R
    Alcohol Clin Exp Res; 2007 Jul; 31(7):1179-87. PubMed ID: 17451401
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nalmefene Mistakenly Prescribed to Reduce Alcohol Consumption in Patients Under Buprenorphine Substitution Therapy Resulting in Acute Opioid Withdrawal: Management in an Emergency Setting.
    Pélissier F; Rougé Bugat ME; Nubukpo P; Franchitto N
    J Clin Psychopharmacol; 2016 Feb; 36(1):100-3. PubMed ID: 26658085
    [No Abstract]   [Full Text] [Related]  

  • 10. Extending the treatment options in alcohol dependence: a randomized controlled study of as-needed nalmefene.
    Mann K; Bladström A; Torup L; Gual A; van den Brink W
    Biol Psychiatry; 2013 Apr; 73(8):706-13. PubMed ID: 23237314
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Withdrawal syndrome caused by naltrexone in opioid abusers.
    Hassanian-Moghaddam H; Afzali S; Pooya A
    Hum Exp Toxicol; 2014 Jun; 33(6):561-7. PubMed ID: 23690227
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nalmefene. Alcohol dependence: no advance.
    Prescrire Int; 2014 Jun; 23(150):150-2. PubMed ID: 25121147
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Naltrexone--prevention of recurrence in narcotic dependence and in alcoholism].
    Poser W; Ehrenreich H
    Internist (Berl); 1996 Oct; 37(10):1061-7; discussion 1067. PubMed ID: 9019453
    [No Abstract]   [Full Text] [Related]  

  • 14. A randomised, double-blind, placebo-controlled, efficacy study of nalmefene, as-needed use, in patients with alcohol dependence.
    Gual A; He Y; Torup L; van den Brink W; Mann K;
    Eur Neuropsychopharmacol; 2013 Nov; 23(11):1432-42. PubMed ID: 23562264
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Problem drinking and low-dose naltrexone-assisted opioid detoxification.
    Mannelli P; Peindl K; Patkar AA; Wu LT; Tharwani HM; Gorelick DA
    J Stud Alcohol Drugs; 2011 May; 72(3):507-13. PubMed ID: 21513688
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Unintentional rapid opioid detoxification: case report.
    Singh SM; Sharma B
    Psychiatr Danub; 2009 Mar; 21(1):65-7. PubMed ID: 19270623
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Unexpected delirium during Rapid Opioid Detoxification (ROD).
    Golden SA; Sakhrani DL
    J Addict Dis; 2004; 23(1):65-75. PubMed ID: 15077841
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A clinical trial to determine if corelease of morphine and naltrexone from crushed extended-release capsules induces withdrawal in opioid-dependent patients: a descriptive analysis of six patients.
    Setnik B; Roland CL; Goli V; Sommerville K; Webster L
    J Opioid Manag; 2013; 9(2):139-50. PubMed ID: 23709323
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and tolerability of as-needed nalmefene in the treatment of alcohol dependence: results from the Phase III clinical programme.
    van den Brink W; Strang J; Gual A; Sørensen P; Jensen TJ; Mann K
    Expert Opin Drug Saf; 2015 Apr; 14(4):495-504. PubMed ID: 25652768
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparing Nalmefene and Naltrexone in Alcohol Dependence: Are there any Differences? Results from an Indirect Meta-Analysis.
    Soyka M; Friede M; Schnitker J
    Pharmacopsychiatry; 2016 Mar; 49(2):66-75. PubMed ID: 26845589
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.